Accessibility Statement Skip Navigation
  • Resources
  • Blog
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All Public Company News
      • All Multimedia News
      • View All News Releases

      • Regulatory News

      • D/A/CH Regulatory News
      • UK Regulatory News
      • View All Regulatory News

  • Business & Money
      • Auto & Transportation

      • Aerospace & Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads & Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking & Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers & Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalisation
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls & Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil & Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defence
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation & Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking & Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers & Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines & Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics & Personal Care
      • Fashion
      • Food & Beverages
      • Furniture & Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewellery
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks & Tourist Attractions
      • Gambling & Casinos
      • Hotels & Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Animal Welfare
      • Corporate Social Responsibility
      • Economic News, Trends & Analysis
      • Education
      • Environmental
      • European Government
      • Labour & Union
      • Natural Disasters
      • Not For Profit
      • Public Safety
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Overview
  • Distribution
  • Paid Placement
  • Multimedia
  • Disclosure Services
  • SocialBoost
  • Rooms
    • MediaRoom
    • ESG Rooms
  • AI Tools
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Hamburger menu
  • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
  • Send a Release
    • Phone

    • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

    • ALL CONTACT INFO
    • Contact Us

      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT

  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • News in Focus
    • Browse News Releases
    • Regulatory News
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • Overview
  • Distribution
  • Paid Placement
  • Multimedia
  • Disclosure Services
  • Cision Communications Cloud®
  • AI Tools
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists

InSilicoTrials' research paper published in the Special Issue "Modeling for Advancing Regulatory Science" by Annals of Biomedical Engineering (ABME)


News provided by

InSilicoTrials

26 Jan, 2023, 09:26 GMT

Share this article

Share toX

Share this article

Share toX

MILAN, Jan. 26, 2023 /PRNewswire/ -- InSilicoTrials, leading player in using artificial intelligence (AI) and Modeling & Simulation (M&S) for drug and medical device development, is proud to announce that its research paper, Accelerating Digitalization in Healthcare with the InSilicoTrials Cloud-Based Platform: Four Use Cases, has been selected to be part of the Special Issue "Modeling for Advancing Regulatory Science", released by Annals of Biomedical Engineering (ABME) in occasion of the 50th anniversary of the Biomedical Engineering Society.

Continue Reading
This image opens in the lightbox
Schematic representation of the InSilicoTrials.com collaborative model

Computational modeling and simulation can provide unique insights on how human biology and physiology work and why. In November 2022, the FDA published its first report on the Successes and Opportunities in Modeling & Simulation for FDA, highlighting a selection of modeling and simulation case studies from across FDA and illustrating how these technologies have already been embraced and are playing an important role in helping FDA promote public health.

The Special Issue, which was published on December 23rd, 2022, features an editorial by Tina M. Morrison, Joel D. Stitzel & Steve M. Levine - FDA's office of Regulatory Science and Innovation – entitled Modeling and Simulation in Biomedical Engineering: Regulatory Science and Innovation for Advancing Public Health. The authors highlight how the potential of CM&S (Computer Modeling and Simulation) to overcome obstacles in enhancing medical treatments has been well-established.

The editorial recalls that in the last few of years, Congress has urged FDA "to engage with device and drug sponsors to explore greater use, where appropriate, of in silico [clinical] trials for advancing new devices and drug therapy applications." This highlights a "shift toward a greater reliance on digital evidence from in silico methods in healthcare, opening the door to regulatory pathways in which a collection of computer-based models may be used to reduce, refine, and partially replace both in vivo animal and human experimentation for regulatory purposes."

The editorial concludes that "the practices we establish today will determine the health of all future generations. The time is now to make the necessary changes, not just to advance and translate science, but to create an equitable and foremost healthcare system based upon it."

InSilicoTrials is proud and honored to be part of this process, together with its strong network of scientific partners, creating the biggest collection of in silico tools, and democratizing access to this technology for the industry.

InSilicoTrials' paper discusses four use cases of in silico trials performed using the InSilicoTrials.com platform for modeling and simulation, providing insights on how the technology can be used to accelerate the development of new treatments and medical devices. The first application illustrates how in silico approaches can improve the early nonclinical assessment of drug-induced cardiotoxicity risks. The second use case is a virtual reproduction of a bench test for the safety assessment of transcatheter heart valve substitutes. The third and fourth use cases are examples of virtual patients' generation to evaluate treatment effects in multiple sclerosis and prostate cancer patients, respectively.

"We are honored to have our work recognized by the FDA and ABME," said Luca Emili, CEO of InSilicoTrials. "Modeling and simulation are becoming increasingly important in the drug and medical device development process, and we believe that our cloud-based platform can play a significant role in helping to accelerate the uptake of these technologies."

An important step in this direction has already been made with the FDA Modernization Act 2.0 (FDAMA 2.0), a bill aiming to modernize and improve the regulatory process for drugs, with the goal of getting safe and effective products to market more quickly. Animal testing on new medications will no longer be required for FDA approval, thanks to legislation signed by US President Joe Biden at the end of last month. 
The bill represents a radical shift in the way drugs and treatments will be developed.

The InSilicoTrials' platform is designed to make it easy for researchers and companies to access the latest modeling and simulation tools and resources, without the need for expensive hardware or software. The platform is regulatory compliant and has been used by several leading pharmaceutical and medical device companies.

The Special Issue is available for free download: https://link.springer.com/journal/10439/volumes-and-issues/51-1, while  the InSilicoTrials' paper can be accessed directly via the following link: https://link.springer.com/article/10.1007/s10439-022-03052-6

The PDF version of this press release can be found here: https://insilicotrials.com/wp-content/uploads/2023/01/Press_Release_January23.pdf

About InSilicoTrials

InSilicoTrials is a company that specializes in using artificial intelligence (AI) and simulations to improve drugs and medical device development. It uses machine learning techniques to analyze large amounts of data and make predictions about the safety and efficacy of potential drug compounds and medical devices.

Our goal is to help pharmaceutical, medtech companies and researchers develop new drugs more efficiently and at a lower cost by reducing the need for traditional, time-consuming, and expensive clinical trials. With its cloud-based platform offering advanced M&S tools to perform in silico trials analyses, InSilicoTrials supports companies to integrate AI and simulation technology into their drug development workflows.

InSilicoTrials is currently working on four projects funded by the European Commission: In Silico World, SimCardioTest, Brainteaser & Disc4All.

Photo - https://mma.prnewswire.com/media/1989839/InSilicoTrials.jpg

Modal title

Also from this source

Breaking Barriers in Healthcare Simulation: AVL and InSilicoTrials

Breaking Barriers in Healthcare Simulation: AVL and InSilicoTrials

AVL and InSilicoTrials (IST) have entered a strategic partnership to integrate premier computational fluid dynamics software, AVL FIRE™ M, into...

InSilicoTrials Wins AI Startup of the Year Award at Startup Grind Global 2024

InSilicoTrials Wins AI Startup of the Year Award at Startup Grind Global 2024

InSilicoTrials (IST) is honored to have received the AI Startup of the Year award at Startup Grind Global 2024 in Silicon Valley, California. IST won ...

More Releases From This Source

Explore

Health Care & Hospitals

Health Care & Hospitals

Medical Pharmaceuticals

Medical Pharmaceuticals

Computer & Electronics

Computer & Electronics

STEM (Science, Tech, Engineering, Math)

STEM (Science, Tech, Engineering, Math)

News Releases in Similar Topics

Contact PR Newswire

  • +44 (0)20 7454 5110
    from 8 AM - 5:30 PM GMT
  • General Enquiries
  • Media Enquiries
  • Partnerships

Products

  • Content Distribution
  • Multimedia Services
  • Disclosure Services
  • Cision Communications Cloud®

About

  • About PR Newswire
  • About Cision
  • Partnering Opportunities
  • Careers
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
  • Data Privacy

Do not sell or share my personal information:

  • Submit via Privacy@cision.com 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
+44 (0)20 7454 5110
from 8 AM - 5:30 PM GMT
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 PR Newswire Europe Limited. All Rights Reserved. A Cision company.